TPA 3.0-4.5 Hours After Acute Stroke: A Subgroup Analysis

Professor of Neurology, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Director, Stroke Program, Northwestern Memorial Hospital, Chicago, Illinois

Disclosure: Mark J. Alberts, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AGA Medical Corporation; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; EKR Therapeutics Inc.; Genentech, Inc.; Pfizer Inc.; sanofi-aventis; Takeda Pharmaceuticals North America, Inc.; The Medicines Company
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; EKR Therapeutics Inc.; PhotoThera; sanofi-aventis; Schering-Plough Corporation
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; diaDexus, Inc.; EKR Therapeutics Inc.; Genentech, Inc.; sanofi-aventis; The Medicines Company
Served on the review panel for: Mitsubishi Pharma America, Inc.; Schering-Plough Corporation
Received royalties from: Duke University/Athena Neurosciences, Inc. for ApoE Genotype test